secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2025-05-23T23:59:59+00:00
Accession:  0001437749-25-018358
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech receives Nasdaq delisting notice for failing minimum stockholders' equity rule
--------------------------------------------------------------------------------

- Nasdaq notified Moleculin on May 23, 2025, that it does not meet Listing Rule 5550(b)(1) requiring $2.5M in stockholders' equity.
- The company has 45 calendar days to submit a plan to regain compliance; if accepted, a 180-day extension may be granted.
- Failure to regain compliance could lead to delisting from the Nasdaq Capital Market; no immediate effect on trading.
- The company may appeal any adverse Staff determination to the Nasdaq Hearings Panel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925018358/0001437749-25-018358-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774925018358/mbrx20250523_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-018358

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer